These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. Kim KH; Pyo H; Lee H; Oh D; Noh JM; Ahn YC; Yoon HI; Moon H; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ku BM; Ahn MJ; Shin EC Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):415-425. PubMed ID: 35150786 [TBL] [Abstract][Full Text] [Related]
7. Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients. Shirasuna K; Ito M; Matsuda T; Enomoto T; Ohara Y; Yamamoto M; Nishijima S; Ohkohchi N; Kuromitsu S PLoS One; 2020; 15(12):e0243643. PubMed ID: 33370317 [TBL] [Abstract][Full Text] [Related]
8. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001 [TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Crist M; Iyer G; Hsu M; Huang WC; Balar AV Ther Adv Urol; 2019; 11():1756287219839285. PubMed ID: 31057668 [TBL] [Abstract][Full Text] [Related]
12. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Zhang T; Harrison MR; O'Donnell PH; Alva AS; Hahn NM; Appleman LJ; Cetnar J; Burke JM; Fleming MT; Milowsky MI; Mortazavi A; Shore N; Sonpavde GP; Schmidt EV; Bitman B; Munugalavadla V; Izumi R; Patel P; Staats J; Chan C; Weinhold KJ; George DJ Cancer; 2020 Oct; 126(20):4485-4497. PubMed ID: 32757302 [TBL] [Abstract][Full Text] [Related]
14. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy accelerates immune-senescence and functional impairments of Vδ2 Bruni E; Cazzetta V; Donadon M; Cimino M; Torzilli G; Spata G; Leonardi G; Dieli F; Mikulak J; Mavilio D J Immunother Cancer; 2019 Dec; 7(1):347. PubMed ID: 31829255 [TBL] [Abstract][Full Text] [Related]
16. Exhaustion and senescence of CD4 and CD8 T cells that express co-stimulatory molecules CD27 and CD28 in subjects that acquired HIV by drug use or by sexual route. Bănică L; Vlaicu O; Jipa R; Abagiu A; Nicolae I; Neaga E; Oţelea D; Paraschiv S Germs; 2021 Mar; 11(1):66-77. PubMed ID: 33898343 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in the treatment of advanced urothelial cancer. Lundgren KT; Farina MS; Bellmunt J Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016 [TBL] [Abstract][Full Text] [Related]
18. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study. Yan Y; Wang X; Liu C; Jia J BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541 [TBL] [Abstract][Full Text] [Related]
19. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]